Vandetanib, 443913-73-3, 25 mg, Each

Details:

A broad spectrum, orally available kinase inhibitor that targets primarily tyrosine kinases, including vegfr and egfr, with ic50 values in the nanomolar range; also potently blocks non-receptor tyrosine kinases, including abl, ret, and src, as well as several serine/threonine kinases 443913-73-3